HAYWARD, Calif.–(BUSINESS WIRE)–Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today announced that Bob Goeltz will join Arcus as Chief Financial Officer on August 1, 2020. Mr. Goeltz is a proven financial leader with substantial operational experience in both large and small cap biopharmaceutical company environments.
“Following the recent announcement of our 10-year collaboration with Gilead and successful $348 million financial offering, combined with our growing portfolio of programs, I am confident Bob will play an integral role in advancing Arcus through our next phase of growth towards commercialization and beyond,” said Terry Rosen, Ph.D., Chief Executive Officer of Arcus. “Bob’s experience in navigating the strategic and operational decisions necessary to transition the opportunities derived from an intense, deep and innovative R&D effort through the commercialization process to broadly benefit patients will be central to Arcus’s future success. With the potential to have three molecules in registrational studies in 2021, a prolific discovery team and a uniquely enabling and nascent alliance with Gilead, Bob joins Arcus at a seminal inflection point, with the opportunity to make Arcus’s vision of creating, developing and commercializing innovative and curative therapies for cancer a reality.”
“I had the opportunity to work closely with several of the current Arcus team members during my time at Amgen and Tularik,” said Mr. Goeltz. “It is an honor to join them and the outstanding team that they have assembled since the company’s inception in 2015 and contribute to its mission of delivering clinically meaningful and transformative therapies in the oncology setting. I look forward to providing strategic financial guidance to help deliver on the great promise of Arcus.”
Mr. Goeltz has an extensive track record and breadth of experience in finance and accounting, most recently serving as Chief Financial Officer and Senior Vice President of UNITY Biotechnology and immediately before that as Chief Financial Officer of CytomX Therapeutics, leading both of the companys’ IPOs and finance organizations. Prior to these positions, Mr. (Read more…) Goeltz had an 11-year tenure at Amgen, holding positions including the Chief Financial Officer of Onyx Pharmaceuticals after its acquisition by Amgen, and senior financial roles in commercial and R&D finance, business development and accounting. In his roles at Amgen, he was involved in multiple oncology product launches. Earlier in his career, he served as Director of Finance for Tularik. Mr. Goeltz began his career in the audit practice of EY.
Mr. Goeltz received his Master of Business Administration degree from UCLA’s Anderson School of Management and his Bachelor of Business Administration degree from Emory University’s Goizueta School of Business.
About Arcus Biosciences
Arcus Biosciences is an oncology-focused biopharmaceutical company leveraging its deep cross-disciplinary expertise to discover highly differentiated therapies and to develop a broad portfolio of novel combinations addressing significant unmet needs. AB928, the first and only dual A2a/A2b adenosine receptor antagonist in the clinic, is being evaluated in several Phase 1b/2 studies across multiple indications, including prostate, colorectal, non-small cell lung, pancreatic, triple-negative breast and renal cell cancers. AB680, the first small-molecule CD73 inhibitor in the clinic, is in Phase 1 development for first-line treatment of metastatic pancreatic cancer. AB154, an anti-TIGIT monoclonal antibody, is in Phase 2 development for first-line treatment of metastatic non-small cell lung cancer in combination with zimberelimab and AB928. Zimberelimab (AB122), Arcus’s anti-PD1 monoclonal antibody, is being evaluated in a Phase 1b study as monotherapy for cancers with no approved anti-PD1 treatment options, as well as in combinations across the portfolio. For more information about Arcus Biosciences, please visit www.arcusbio.com.
Forward Looking Statements
This press release contains forward-looking statements. All statements other than statements of historical facts contained herein, including, but not limited to, the statements regarding Arcus’s vision, advantages and opportunities, are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All forward-looking statements involve known and unknown risks, uncertainties and other important factors that may cause Arcus’s actual results, performance or achievements to differ significantly from those expressed or implied. Factors that could cause or contribute to such differences include, but are not limited to, the inherent uncertainty associated with the COVID-19 pandemic, including the duration and/or severity of the outbreak and actions by government authorities to slow the spread of the virus, risks associated with our collaboration arrangements with Gilead and our ability to obtain regulatory clearance for the transactions contemplated with Gilead, the inherent uncertainty associated with pharmaceutical product development and clinical trials, the emergence of adverse events or other undesirable side effects, and changes in the competitive landscape for our programs. Risks and uncertainties facing Arcus are described more fully in Arcus’s most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q filed with the U.S. Securities and Exchange Commission. You are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date of this press release. Arcus disclaims any obligation or undertaking to update, supplement or revise any forward-looking statements contained in this press release.
The Arcus name and logo are trademarks of Arcus. All other trademarks belong to their respective owners.
Source: Arcus Biosciences
Contacts
Katherine Bock
(510) 694-6231